Literature DB >> 1721565

Levels of GH binding activity, IGFBP-1, insulin, blood glucose and cortisol in intensive care patients.

R J Ross1, J P Miell, J M Holly, H Maheshwari, M Norman, A F Abdulla, C R Buchanan.   

Abstract

OBJECTIVE: To investigate levels of serum GH binding activity, insulin-like growth factor binding protein-1 (IGFBP-1), blood glucose, serum insulin, and cortisol in patients on the Intensive Therapy Unit.
DESIGN: Case-control study of severely ill patients admitted to the Intensive Therapy Unit. PATIENTS: Six critically ill patients (51-78 years) who required ventilatory and nutritional support and six healthy age, sex, height and weight matched controls. MEASUREMENTS: Patients and controls were studied for two 24-hour periods; the patients before and after commencing parenteral nutrition, the controls whilst fasted and on a second occasion when fed a diet equal in protein and calories to that of the patients' parenteral nutrition. Samples were taken hourly for measurement of IGFBP-1, blood glucose, serum insulin and cortisol. Growth hormone binding activity was measured at 0 hours.
RESULTS: Blood glucose levels were higher in the patients than controls in both the fasted (mean +/- SEM 5.1 +/- 0.5 vs 3.8 +/- 0.2 mmol/l, P = 0.04) and fed states (10.1 +/- 1.6 vs 5.0 +/- 0.1 mmol/l, P = 0.02) and patients' insulin levels were also higher when fed (81.5 +/- 31.6 vs 24.2 +/- 4.8 mU/l, P = 0.046) although there were no significant differences between patients and controls when fasted. IGFBP-1 levels were inversely related to insulin levels in both the patients and controls; mean IGFBP-1 concentrations were higher in fasted patients than in controls (123 +/- 38 vs 52 +/- 9, P = 0.046) but when fed, both groups had similar mean levels. Serum GH binding activity was low in the patients and did not change with feeding. Mean 24-hour cortisol levels were higher in the patients than in controls, whether fasted or fed, and showed no nyctohemeral rhythm.
CONCLUSIONS: We have previously reported that critically ill patients have low levels of IGF-I with augmented basal levels of GH. The present results demonstrate that these changes in the GH-IGF-I axis are associated with insulin resistance with respect to blood glucose and high levels of IGFBP-1 when patients are fasted. However, when fed, the inverse relationship of IGFBP-1 to insulin is preserved. Patients have low levels of GH binding activity and increased mean cortisol levels. Interventional studies in this patient group with GH and IGF-I must take account of these changes in binding protein and cortisol levels.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1721565     DOI: 10.1111/j.1365-2265.1991.tb03549.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  13 in total

1.  Serum cortisol and thyroid hormone levels in neonates with sepsis.

Authors:  B K Das; Pooja Agarwal; J K Agarwal; O P Mishra
Journal:  Indian J Pediatr       Date:  2002-08       Impact factor: 1.967

Review 2.  Dynamic testing in Cushing's syndrome.

Authors:  Blerina Kola; Ashley B Grossman
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 3.  [Cellular regulation of anabolism and catabolism in skeletal muscle during immobilisation, aging and critical illness].

Authors:  Eva-Maria Strasser; Barbara Wessner; Erich Roth
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

4.  The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; John Newell-Price; Martin O Savage; Paul M Stewart; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2008-03-11       Impact factor: 5.958

Review 5.  Cushing's syndrome: update on signs, symptoms and biochemical screening.

Authors:  Lynnette K Nieman
Journal:  Eur J Endocrinol       Date:  2015-07-08       Impact factor: 6.664

Review 6.  The role of insulin, growth hormone and IGF-I as anabolic agents in the critically ill.

Authors:  R J Ross; J Rodriguez-Arnao; J Bentham; J H Coakley
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

Review 7.  Medical therapy for Cushing's disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers.

Authors:  Maria Fleseriu; Stephan Petersenn
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

Review 8.  Circulating growth hormone binding proteins.

Authors:  G Baumann; M A Shaw; K Amburn
Journal:  J Endocrinol Invest       Date:  1994-01       Impact factor: 4.256

9.  Activity of GH/IGF-1 axis in burn patients: comparison with normal subjects and patients with GH deficiency.

Authors:  L Gianotti; M Stella; D Bollero; F Broglio; F Lanfranco; G Aimaretti; S Destefanis; M Casati; G Magliacani; E Ghigo
Journal:  J Endocrinol Invest       Date:  2002-02       Impact factor: 4.256

10.  Effects of growth hormone and insulin-like growth factor-1 on postoperative muscle and substrate metabolism.

Authors:  Folke Hammarqvist; Ingmar Wennström; Jan Wernerman
Journal:  J Nutr Metab       Date:  2009-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.